Anti-VSIG4 Antibodies Convert M2 Macrophages to M1 Phenotype
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are inadequate in effectively targeting and converting tumor-associated macrophages (TAMs) from a pro-tumoral M2 phenotype to an anti-tumoral M1 phenotype, limiting their therapeutic efficacy in cancer management.
Innovation Solution
Development of humanized antibodies specifically binding to VSIG4, which interact with M2 macrophages to convert them into M1 macrophages, thereby inducing CD8+ T cell proliferation and pro-inflammatory cytokine secretion, thereby suppressing cancer progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments are used, then general cancer therapy is provided, but tumor-associated macrophages are not effectively targeted for conversion from M2 to M1 phenotype
Solution Approach 1:
The patent uses anti-VSIG4 antibodies as intermediary agents that specifically bind to VSIG4 receptors on M2 macrophages, mediating their conversion to M1 phenotype. This intermediary approach enables precise targeting of TAMs without affecting other cell types, resolving the contradiction between general therapy reliability and specific targeting capability.
Solution Approach 2:
The patent changes the functional state parameter of macrophages by inducing phenotype conversion from M2 (pro-tumoral) to M1 (anti-tumoral). This parameter change in macrophage polarization state directly addresses the limitation of current treatments that cannot effectively modify the functional state of TAMs.
2Adaptability or versatility
If M2 macrophages are targeted for conversion, then anti-tumoral immunity is enhanced, but current methods lack the specificity to achieve effective conversion
Solution Approach 1:
Anti-VSIG4 antibodies serve as specific mediators that recognize and bind to VSIG4 receptors uniquely expressed on M2 macrophages. This specific recognition enables reliable and effective phenotype conversion without affecting other cell types, resolving the contradiction between conversion capability and conversion efficacy.
Solution Approach 2:
The patent applies local quality by targeting a specific receptor (VSIG4) that is locally expressed on M2 macrophages. This localized targeting approach ensures that only M2 macrophages are converted to M1 phenotype, achieving both high adaptability in macrophage conversion and high reliability in conversion efficacy.
3Adaptability or versatility
If tumor-associated macrophages are not effectively targeted, then current treatment limitations persist, but new therapeutic approaches are needed
Solution Approach 1:
The patent introduces anti-VSIG4 antibodies as new intermediary therapeutic agents that specifically target M2 macrophages. This new intermediary approach provides both therapeutic versatility (new mechanism of action) and treatment reliability (effective tumor suppression through M1 conversion), resolving the contradiction between needing new approaches and ensuring reliable outcomes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of anti-VSIG4 antibodies effectively converts M2 macrophages to M1 macrophages, enhancing CD8+ T cell proliferation and pro-inflammatory cytokine production, leading to significant tumor suppression and improved cancer treatment outcomes.
Implementation Method 1
humanized antibodies specifically binding to VSIG4, which interact with M2 macrophages to convert them into M1 macrophages
Data Source
AI summary
It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.